Treatment approaches in patients with diabetic nephropathy

Prikolota A.V.

M. Gorky Donetsk State Medical University, Donetsk, Russia

Diabetic nephropathy (DN), which develops in 30–40% of patients with type 1 and type 2 diabetes mellitus, remains one of the leading causes of end-stage chronic kidney disease and is associated with high cardiovascular risk. Essential components of the treatment strategy include lifestyle modification, achieving target blood pressure levels using renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter type 2 inhibitors, and the addition of a nonsteroidal mineralocorticoid receptor antagonist (finerenone) in cases of persistent albuminuria. Glycemic control should be achieved with medications with proven cardiorenoprotective properties. This review, based on an analysis of current international guidelines, highlights the need for a multidisciplinary approach to the timely administration of combination nephroprotective therapy and improving long-term renal and cardiovascular prognosis in patients with diabetic nephropathy.

For citations: Prikolota A.V. Treatment approaches in patients with diabetic nephropathy. Pharmateca. 2026;33(2):13-22. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.2.13-22

Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.

Keywords

About the Authors

A.V. Prikolota, Cand. Sci. (Med.), Associate Professor, Department of Therapy named after Professor A.I. Dyadyk, M. Gorky Donetsk State Medical University, Donetsk, Russia; prikav@yandex.ru, ORCID: https://orcid.org/0000-0002-9128-2511

Similar Articles